Chimerix

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Chimerix transitions successfully, eyes oncology pipeline growth

Chimerix navigated a key transition in 2022, focusing on oncology pipeline
Financially, the company aims to fund operations into 2027
Promising clinical data on ONC201 and ONC206 highlight potential market opportunities

Chimerix reports operational and financial progress, poised for oncology growth

Chimerix demonstrated operational and financial progress in Q1 2023, with a strong focus on advancing its oncology pipeline and addressing analyst inquiries.
The company's innovative research capabilities, promising drug candidates, and solid financial position position it well for future growth and success.

Chimerix reports robust Q2 performance and strategic leadership recruitment

Chimerix's strong performance in global engagement and dose escalation studies positions them well for future growth in targeted oncology.
Maintaining financial discipline and leadership recruitment indicate a strategic approach to capital allocation and pipeline expansion.
Clear evaluation criteria and data sharing timelines will be crucial for addressing challenges and seizing opportunities in advancing their programs.

Chimerix (CMRX) advances oncology studies, poised for commercialization success

Chimerix (CMRX) showcased progress in ONC201 and ONC206 studies, with a focus on scientific validation and commercialization readiness.
Financially stable with a cash balance of $217 million, the company is well-positioned for future growth and operational sustainability.
Engagement with the medical community and strategic planning for market entry highlight Chimerix's commitment to innovation and patient care.

Chimerix reports disciplined finances, positive trial results, eyes global expansion

Chimerix showcased financial discipline amidst a net loss, while emphasizing positive Phase II results of ONC201. The company is focused on advancing the Phase III ACTION study with global enrollment and strategic management appointments. Challenges include timely execution of the study and managing enrollment trends, with opportunities in commercialization and partnerships.

Chimerix reports robust Q1 earnings, eyes global drug approvals

Chimerix's Q1 2024 earnings call highlighted strong financials, progress in key studies, and strategic growth initiatives. While facing challenges in enrollment, regulatory pathways, and commercialization, the company remains optimistic about its pipeline and financial discipline.

Chimerix advances key studies, maintains strong finances amid challenges

Chimerix (CMRX) demonstrated progress in key clinical studies and maintained a strong financial position in Q2 2024.
While facing challenges with increased R&D expenses and a net loss, the company is strategically investing in growth opportunities.
Opportunities lie in potential drug registrations, intensified dosing schedules, and investments in launch readiness for future success.
Overall, Chimerix remains focused on advancing its pipeline and financial strategy to drive long-term value for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.

Chimerix (CMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Chimerix (CMRX) Upgraded to Buy: What Does It Mean for the Stock?

Highlights Confidence in Ongoing Strategy and Future Clinical Development Plans Highlights Confidence in Ongoing Strategy and Future Clinical Development Plans

Chimerix Responds to Rubric Capital Management

NEW YORK--(BUSINESS WIRE)--Rubric Capital Management LP (“Rubric”), an investment adviser whose managed funds and accounts collectively own approximately 8.5% of the common stock of Chimerix, Inc. (“Chimerix” or the “Company”) (NASDAQ: CMRX), today sent a letter to Chimerix's Board of Directors (the “Board”).

Rubric Capital Management Sends Letter to Chimerix Board of Directors

Chimerix, Inc. (NASDAQ:CMRX ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President-Strategic Planning & Investor Relations Mike Sherman - Chief Executive Officer Mike Andriole - Chief Business Officer & Chief Financial Officer Allen Melemed - Chief Medical Officer Conference Call Participants Kevin Strang - Jefferies Naureen Quibria - Capital One Ed White - H.C. Wainwright Joseph Thome - Cowen Operator Good morning, ladies and gentlemen, and welcome to the Chimerix Third Quarter 2022 Earnings Conference Call.

Chimerix, Inc. (CMRX) Q3 2022 Earnings Call Transcript

Arcus Biosciences

Vista Oil & Gas SAB de CV

Chimerix (CMRX), Vista Oil & Gas (VIST) and Arcus Biosciences (RCUS) have been selected as the top picks with a high net income ratio.

Buy 3 of the Best Stocks by Using Net Income Ratio

Chimerix (CMRX) delivered earnings and revenue surprises of 30.95% and 84.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Chimerix (CMRX) Beats Q3 Earnings Estimates

– ONC201 Phase 3 ACTION Study On-Track to Open Enrollment in November –

Chimerix Reports Third Quarter 2022 Financial Results and Provides Operational Update

DURHAM, N.C., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 3, 2022 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2022, and to provide a business overview.

Chimerix to Report Third Quarter 2022 Financial Results and Provide an Operational Update on November 3, 2022

Chimerix (CMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Chimerix (CMRX) Earnings Expected to Grow: What to Know Ahead of Q3 Release

- $238 Million in Upfront Payment Received at Closing with Additional $136.5 Million in Potential Milestone Payments Plus Royalties -

Chimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions

DURHAM, N.C., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a pre-recorded corporate presentation at the H.C. Wainwright 24th Annual Global Investment Conference made available on Monday, September 12, 2022 at 7:00 a.m. ET.

Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference

- Initial Procurement of 319,000 Treatment Courses for $115M with Additional Procurements at BARDA's Discretion Over 10 Years –

Chimerix Awarded BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox

Chimerix has been a developer of antivirals. Its key antiviral drug, tembexa, got approved last year and is being sold to a third party.

Chimerix: A Confusing Business Strategy Makes It Unconvincing

Initiation of phase 3 ACTION study using ONC201 for treatment of glioma patients who harbor the H3 K27M mutation is expected in the 2nd half of 2022. Interim results from the ACTION study are expected in early 2025, with final results expected in 2026.

Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation

Applied DNA Sciences

Geovax Labs

iShares Genomics Immunology and Healthcare ETF

SIGA Technologies

Tonix Pharmaceuticals Hld

Monkeypox stocks, our topic for today, have had a mostly mixed performance so far in 2022. It is likely, however, that they could benefit from the similar tailwinds enjoyed by companies, such as Pfizer (NYSE: PFE ), BioNTech (NASDAQ: BNTX ), and Moderna (NASDAQ: MRNA ), which have developed the Covid-19 vaccines that have now become household names.

7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher

Chimerix, Inc. (NASDAQ:CMRX ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Michelle LaSpaluto – Vice President-Strategic Planning and Investor Relations Mike Sherman – President and Chief Executive Officer Allen Melemed – Chief Medical Officer Mike Andriole – Chief Financial and Business Officer Randall Lanier – Chief Science Officer Josh Allen – Chief Technology Officer-Imipridones Conference Call Participants Maury Raycroft – Jefferies Joseph Thome – Cowen Ed White – H.C. Wainwright Soumit Roy – Jones Research Operator Good afternoon, ladies and gentlemen, and welcome to the Chimerix Second Quarter 2022 Earnings Conference Call.

Chimerix, Inc's (CMRX) CEO Mike Sherman on Q2 2022 Results - Earnings Call Transcript

– ONC201 Phase 3 ACTION Study Planned to Initiate This Year –

Chimerix Reports Second Quarter 2022 Financial Results and Provides Operational Update

DURHAM, N.C., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Monday, August 8, 2022 at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2022, and to provide a business overview.

Chimerix to Report Second Quarter 2022 Financial Results and Provide an Operational Update on August 8, 2022

Athersys

Comera Life Sciences Holdings Inc

InflaRx

Revelation Biosciences

Biotech penny stocks to watch this week. The post Best Penny Stocks To Buy As Recession Begins?

Best Penny Stocks To Buy As Recession Begins? 5 Biotech Stocks To Watch

Imperial Petroleum

Here's what you need to know about buying penny stocks on July 27th The post What to Know About Buying Penny Stocks on July 27th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on July 27th

If you thought monkeypox was a fad, you might want to reconsider.

Hot Penny Stocks To Watch As Monkeypox Gets WHO GHE Designation

Emergent BioSolutions

Drugs and vaccines used against smallpox are seen as the first line of defense against the rising tide of monkeypox infections. The post Monkeypox Stocks SIGA, GOVX, BVNRY, CHMX, EBS Soar on Global Health Emergency appeared first on InvestorPlace.

Monkeypox Stocks SIGA, GOVX, BVNRY, CHMX, EBS Soar on Global Health Emergency

Stocks related to the treatment of monkeypox are heating up today on news that the U.S. is building a vaccine stockpile and will offer vaccine appointments to individuals who are at risk of contracting the virus. The post Monkeypox Stocks BVNRY, EBS, CMRX, SIGA Heat Up on U.S. Vaccine Stockpile appeared first on InvestorPlace.

Monkeypox Stocks BVNRY, EBS, CMRX, SIGA Heat Up on U.S. Vaccine Stockpile

Jaguar Health

RedHill Biopharma

Can these penny stocks make gains this coming week? The post Hot Penny Stocks to Buy Right Now?

Hot Penny Stocks to Buy Right Now? Check These 3 Out

DURHAM, N.C., June 24, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Public Health Agency of Canada awarded Chimerix a contract up to $25.3 million agreement to procure TEMBEXA® (brincidofovir). Execution of this contract will be the responsibility of Chimerix, as it is expected to substantially occur prior to the close of the pending transaction with Emergent BioSolutions, Inc. (Emergent).

News for Chimerix Stock (CMRX)